Skip to main content
Caplight Logo









Notch Therapeutics

Notch Therapeutics

Private
VancouverHealthcare & Life Scienceshttp://notchtx.com/

Last Round

M&A

Apr 2, 2025

Est. Valuation

$20M

Total Funding Raised

$90M

Company Overview

Notch Therapeutics is a biotechnology company that develops renewable, induced pluripotent stem cell (iPSC)-derived immunotherapies for cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

allogeneic cell therapyiPSCinduced pluripotent stem celloff-the-shelf CAR-TT cell therapyengineered thymic nicheETNcell engineeringoff-the-shelf therapybiotech platformCAR-Toncology therapeuticsimmunologydrug discoveryprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Notch Therapeutics Comparables

Compare Notch Therapeutics with similar companies based on industry and business-model similarity.

Notch Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shinobi Therapeutics, Inc.
84%
Shoreline Biosciences
82%
Rebirthel Co., Ltd.
82%

Notch Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AApr 2, 2025
Series AFeb 10, 2021
SeedNov 1, 2019

Notch Therapeutics Investors

Notable investors and investment history

Notch Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries A
Amplitude VenturesSeries A
CCRMSeries A, Seed
CCRM Enterprises Inc.Series A
Lumira VenturesSeed, Series A
Casdin CapitalSeries A
TIAPSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2025

    Roche Holding led the M&A round.

  • Nov 1, 2019

    $5M round with participation from Lumira Ventures and TIAP.

Notch Therapeutics Filings

Explore SEC and related filing metadata, where available.

Notch Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Notch Therapeutics's valuation, stock price, and market status.

Is Notch Therapeutics a public or private company?

Notch Therapeutics is a private company.

What is the current stock price of Notch Therapeutics?

Notch Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Notch Therapeutics worth (valuation)?

Notch Therapeutics's valuation is estimated at $20.0M based on funding round data.

Can I buy Notch Therapeutics stock?

Notch Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Notch Therapeutics's last funding round?

Notch Therapeutics's most recent funding round was Series A on November 5, 2019.

Who are the main investors in Notch Therapeutics?

Key investors in Notch Therapeutics include EcoR1 Capital, Amplitude Ventures, CCRM, Lumira Ventures, Casdin Capital.

Will Notch Therapeutics IPO soon?

No public IPO plans have been announced for Notch Therapeutics.

How can I track Notch Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Notch Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVancouver
Employee Range8
Year Founded2018
Last FundingApr 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?